Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.32 |
| ▸ | GRM8 | O00222 | 3/20 | 0.32 |
| ▸ | GRM6 | O15303 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394133 | 1.00 | FUCA1 (0.32) | FUCA1GRM4GRM8GRM6ALDH1A1 | |
| SCHEMBL5390585 | 1.00 | FUCA1 (0.32) | FUCA1GRM4GRM8GRM6ALDH1A1 | |
| SCHEMBL5394130 | 1.00 | FUCA1 (0.32) | FUCA1GRM4GRM8GRM6ALDH1A1 | |
| SCHEMBL5537093 | 1.00 | FUCA1 (0.32) | FUCA1GRM4GRM8GRM6ALDH1A1 | |
| SCHEMBL6880715 | 0.87 | CYP1A2 (0.34) | — | |
| SCHEMBL5382379 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL5394072 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL5394201 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL5388548 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL5382375 | 0.78 | CYP1A2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047678-B1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER LAMBERT CO (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | claimed |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | DOOLEY DAVID JAMES (US) | 2004-01-08 | — | — | US | claimed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7138542-B2 | Method of treating tinnitus | WARNER LAMBERT COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060100281-A1 | Method of treating tinnitus | DOOLEY DAVID J | 2006-05-11 | — | — | US | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6518289-B1 | Especially irritable bowel syndrome | PFIZER, INC. | 2003-02-11 | — | — | US | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-1047678-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999031075-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885GRM4 979/4885GRM8 1040/4885 |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885GRM4 979/4885GRM8 1040/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | FUCA1 521/4885GRM4 1370/4885GRM8 2070/4885 |
| US-20060100281-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRB2 | FUCA1 1973/4885GRM4 926/4885GRM8 1209/4885 |
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885GRM4 979/4885GRM8 1040/4885 |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885GRM4 979/4885GRM8 1040/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | FUCA1 521/4885GRM4 1370/4885GRM8 2070/4885 |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | GABRB2, GABBR1, GABBR2 | FUCA1 2920/4885GRM4 135/4885GRM8 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.